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Summary
PRINCIPLES: Pituitary adenomas are common intracrani-
al neoplasms that generate symptoms as a result of either
mass effect or the increased production of pituitary hor-
mones. Although mostly benign, these tumours can be as-
sociated with considerable morbidity. We investigated a
panel of immunohistochemical preparations to identify po-
tential therapeutic targets and surrogate markers of clinical
outcome.
METHODS: Tumour tissue from 25 patients was evaluated
for immunohistochemical expression of somatostatin re-
ceptors 1‒5, von Willebrand-factor (vWF), interleukin-8
(IL-8), vascular endothelial growth factor receptor 2
(VEGFR-2), kinesin spindle protein (Eg5) and MIB-1
(Ki-67), and its relationship with clinical features was ana-
lysed.
RESULTS: The proliferation marker MIB-1 (Ki-67) was
the only marker predictive of adenoma recurrence. Of note,
67% of all relapses were associated with tumours showing
luteinising hormone expression. All pituitary adenomas
showed variable somatostatin receptor, IL-8, Eg5, vWF
and VEGFR-2 expression; a relationship between these
parameters and clinical outcome could not be demonstrated
in this cohort.
CONCLUSIONS: This study validates MIB-1 (Ki-67) as
a reliable marker of tumour recurrence in pituitary ad-
enomas. Considering the consistently increased expression
of Eg5, IL-8, VEGFR-2, somatostatin receptors and vWF
in these tumours, further investigation as potential thera-
peutic targets is warranted.
Key words: biomarker, outcome, pituitary adenoma,
recurrence, somatostatin receptors, angiogenesis,
proliferation
Introduction
Pituitary adenomas represent common, almost always be-
nign intracranial neoplasms that are primarily found in
adults during the 3rd‒6th decades [1]. Although pituitary
adenomas have been studied extensively, the relationship
between histopathological features and clinical outcome re-
mains imprecise [1–5]. Even benign tumours may recur
and cause significant morbidity and, rarely, mortality.
Atypical adenomas show a greater degree of invasion of
surrounding structures and higher recurrence rates. These
tumours, comprising about 15% of adenomas, possess in-
creased proliferative activity characterised by more than
occasional mitoses, MIB-1 (Ki-67) labelling exceeding
3%, and significant p53 immunoreactivity [2–5, 43]. Al-
though most carcinomas show elevated mitoses, their mor-
phological features are not always overtly malignant [1–5].
Thus, there is a critical need for new therapies for aggress-
Figure 1
Immunohistochemical expression of the different markers‘
expression in a pituitary adenoma: (A) hematoxilin-eosin, (B)
reticulin, (C) MIB-1 (Ki-67), (D) Eg5, (E) VEGFR-2, (F) vWF, (G)
IL-8, (H) SSTR-1, (I) SSTR-2, (J) SSTR-3, (K) SSTR-4, (L)
SSTR-5.
Eg5 = kinesin spindle protein; IL-8 = interleukin-8; SSTR =
somatostatin receptor; VEGFR-2 = vascular endothelial growth
factor receptor-2; vWF = von Willebrand-factor
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ive tumours and biomarkers that reliably predict the biolo-
gical behaviour of pituitary adenomas.
The optimal treatment of pituitary adenomas encompasses
invasive and noninvasive options and depends on multiple
factors, including size, hormone production and the degree
of invasion into surrounding structures. Minimally invas-
ive, endoscopic transsphenoidal surgery is now firmly es-
tablished as the gold-standard of treatment. Although sur-
gery remains the first-line choice, invasive and/or refract-
ory pituitary adenomas often present therapeutic chal-
lenges. For example, dopamine agonists have proven ef-
fective in prolactinomas, and most of these tumours can
be managed exclusively with conservative therapy. So-
matostatin (somatotrophin release-inhibiting factor, SRIF)
is a polypeptide hormone highly expressed in corticotroph
adenomas [7, 23]. According to their affinity profile for
somatostatin analogues (SSAs), there are two subfamilies
of somatostatin receptors (SSTRs), which translate into
specific pharmacological properties: (1.) SRIF-1, compris-
ing SSTR-2, SSTR-3 and SSTR-5, and (2.) SRIF-2, in-
cluding SSTR-1 and SSTR-4 [7–9]. Octreotide and lanre-
otide bind with a high affinity to SSTR-2, moderate affinity
to SSTR-3 and SSTR-5, and have low or absent affinity
to SSTR-1 and SSTR-4 [7, 10]. Currently, SSAs are the
mainstay of medical therapy for somatotroph adenomas, al-
though they lack efficacy in patients with certain genetic
forms of the disease [42]. Furthermore, although incom-
pletely understood, data regarding resistance and the un-
derlying mechanisms of certain pituitary adenomas are ac-
cruing[42]. SOM230 (pasireotide), a new multiligand SSA
that binds to all SSTRs except SSTR-4, has been invest-
igated in clinical trials for pituitary adenomas [11, 12, 15,
16] and is now registered for treatment of patients with
Cushing’s disease in most European countries. DG3173
is a heptapeptide SSA with a novel amino acid sequence
and unique cyclic backbone. In addition to its affinity to
SSTR-2 and SSTR-5, it is the only SSA that binds to
SSTR-4 [13]. Preliminary studies with SSAs support fur-
ther investigation as treatment for relapsed/refractory pitu-
itary adenomas [7, 14].
Inhibition of angiogenesis has shown at least partial effic-
acy in a variety of cancers and has prompted interest as
an alternative therapy in aggressive pituitary tumours. The
first case of bevacizumab-treated pituitary carcinoma with
long-term control was recently reported, providing a pos-
sible new option in the management of aggressive pituit-
ary tumours [17]. Another novel antineoplastic strategy is
the targeted destruction of cells undergoing mitosis with
kinesin spindle protein (KSP) inhibitors. In a recent study,
patients with relapsed/refractory solid tumours and lymph-
oma were enrolled in a Phase I trial with AZD4877 (Eg5),
a KSP inhibitor. The agent was generally well-tolerated
and showed therapeutic promise [24], thus providing a po-
tential non-classical approach to chemotherapy. The aims
of this study were to investigate SSTR, proliferation and
angiogenesis markers to better characterise their expression
in different subtypes of pituitary adenoma and to ascertain
their potential clinical and biological role.
Materials and methods
Patients
We conducted a retrospective study of pituitary adenomas
in 25 patients treated and followed up at the University
Hospital of Zurich between 1994 and 2011. Medical re-
cords were reviewed to extract patient characteristics
(gender, age at initial diagnosis, symptoms at presentation,
hormone production clinically, tumour size, type and
nature of therapy). For the purposes of this study, recur-
rence was defined as the emergence of a new radiologically
defined lesion, with the date of recurrence corresponding to
the date of the radiological study. Information on the extent
of resection was obtained from the neurosurgical and ima-
ging records. In patients with subtotal surgical resection,
recurrence was defined as radiological evidence of growth
(increase in size) of the residual lesion.
Endoscopic transsphenoidal surgery was performed as the
first-line treatment, sometimes followed by medical ther-
apy or combined radiation-medical therapy. In all cases, ef-
forts were made to resect as much tumour tissue as pos-
sible, while preserving the function of the surrounding nor-
mal pituitary gland. The study design complied with the
criteria established by the local ethics committee.
Figure 2
Kaplan-Meier curve showing age and recurrence free survival.
Figure 3
Kaplan-Meier curve showing MIB-1 (Ki-67) proliferation index and
time to recurrence: cases with higher MIB-1 proliferation index are
more likely to recur (p <0.0001).
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Tumour samples
All pathology materials, consisting in most cases of
haematoxylin-eosin and reticulin-stained sections, anterior
pituitary immunohistochemistry and the MIB-1 (Ki-67)
proliferation marker, were reviewed to confirm the dia-
gnosis and to select appropriate blocks for additional im-
munohistochemical studies. Only cases with sufficient tis-
sue remaining in the paraffin block were selected. Pituitary
adenoma subtypes were classified in accordance with
World Health Organisation (WHO) 2004 criteria on the
basis of their hormone expression profile (immunophen-
otype) [18]. Additional clinical classification is shown in
table 1 [41].
Immunohistochemistry
Anti-SSTR-1, -3, -4 and -5 antibodies were obtained from
Novartis Pharma AG (Basel, Switzerland). Other antibod-
ies used included anti-SSTR-2 (Gramsch Lab, 1:300),
MIB-1 (KI-67, VentanaRoche, prediluted) and von
Willebrand-factor (vWF, Dako, 1:1000). Antibodies
against Eg5, interleukin-8 (IL-8) and vascular endothelial
growth factor receptor-2 (VEGFR-2) were purchased from
Abcam (Cambridge, UK, 1:100), R&D Systems Europe
Ltd. (Abingdon, UK, 1:10) and Cell Signaling
(BioConcept, Allschwil, Switzerland, 1:400), respectively.
A Leica Bond-Max automated immunostainer employing 4
μm-thick, formalin fixed, paraffin embedded sections was
used, selecting a single representative block from each tu-
mour. Immunohistochemistry conditions were optimised
for each antibody using manufacturers’ recommendations
(fig. 1). Appropriate positive and negative controls were
used as recommended by the manufacturer.
Immunohistochemical evaluation
For screening of antibodies, the staining results were
scored for immunolabelling using a semiquantitative scale.
Specific criteria for evaluating each antibody are detailed
below.
SSTR-1, SSTR-2, SSTR-3, SSTR-4, SSTR-5, Eg5, IL-8
An immunoreactivity score (IRS) was recorded for all sec-
tions, noting the intensity of the colour as well as the per-
centage of cells showing a positive cytoplasmic or mem-
branous staining. The percentage of positive cells was cal-
culated as follows: no positive cells (0); <10% of positive
cells (1); 10%–50% of positive cells (2); 51%–80% of pos-
itive cells (3); >80% of positive cells (4); and the intens-
ity of staining: no staining (0); mild staining (1); moderate
staining (2); strong staining (3). The overall IRS was calcu-
lated as [percentage of positive cells] x [intensity of stain-
ing], and classified as negative (“-“; IRS 0 and 1), weak
expression (positive “+”; IRS 2 and 3), moderate expres-
sion (double positive “++”; IRS 4 to 8) or strong expression
(triple positive “+++”; IRS 9 to 12) [7, 19].
VEGFR-2 and vWF
VEGFR-2 and vWF were found only in vessel endothelial
cells. Immunostaining intensity (vessel density) was as-
sessed with a modified IRS [7, 19], scoring the number
of positive vessels instead: no immunoreactivity (0), <10%
positive vessels (1), 10%–50% positive vessels (2);
51%–80% positive vessels (3); >80% positive vessels (4).
MIB-1 (Ki-67)
The proportion of immunoreactive cells for the nuclear
antibody MIB-1 (Ki-67) was determined by counting the
number of positive cells out of 500 tumour cells in the re-
gion of maximum staining.
Statistical analysis
Difference in the rate of recurrence between groups defined
by receptor expression (e.g. SSTR-1) was tested using the
log-rank (Mantel-Cox) test. For expression of each receptor
type, the mean-value of the expression-level (classified by
the observer) per group was calculated. The results are
summarised in fig. 5. All calculations were performed us-
ing Graph Pad Prism 5. A p-value <0.05 was considered of
statistical significance.
Results
Patient characteristics
The study comprised 9 females and 16 males with a mean
age of 55 years at presentation (range 23–77). The present-
ing complaints are listed in table 1. The mean duration of
follow-up was 67.7 months (range 3.47–114.13). All pa-
tients were treated with either surgery alone (n = 18, 72%),
surgery and medical therapy (n = 5, 20%) or surgery and
radiotherapy (n = 2, 8%). Patients with prolactinomas re-
ceived dopamine agonists as medical therapy, including a
single patient who received it prior to surgery, and the pa-
tients with growth hormone (GH) producing adenomas re-
ceived somatostatin analogues. One patient died of oeso-
Figure 4
SSTR-, IL8-, Eg5-, VEGFR-2- and vWF-expression of the different
pituitary adenoma subtypes. Note that the y-axes represent the
mean immunoreactivity score.
ACTH = adrenocorticotrophic hormone; Eg5 = kinesin spindle
protein; GH = growth hormone; IL-8 = interleukin-8; Prl = prolactin;
SSTR = somatostatin receptor; VEGFR-2 = vascular endothelial
growth facto receptorr-2; vWF = von Willebrand-factor
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phageal carcinoma. Of the remaining patients (n = 24), 4
men and 2 women (24%) underwent a second operation
owing to recurrence. During follow-up, 52% of patients (n
= 13) were tumour free after treatment, whereas 48% (n =
12) showed a stationary residual lesion on imaging.
There was no significant gender difference (p = 0.836)
or relationship with patient age (p = 0.268) and recurrence
rate (fig. 2) regarding the likelihood of recurrence.
Pathological features
Tumours ranged in size from 0.5 to 7 cm in greatest single
dimension, with a mean size of 1.6 cm. There was no sig-
nificant difference in mean size between females (2.14 cm)
and males (1.20 cm). A variety of nonspecific histopath-
ological growth patterns were seen. Mitotic activity was
not significantly elevated. PAs were classified according to
WHO 2004 classification [18] as detailed in table 1. Recur-
rent disease was shown in 24% (6/25) of cases, including
one each of prolactinoma, adrenocorticotrophic hormone
(ACTH) adenoma, mixed GH/prolactin cell adenoma, gon-
adotroph adenoma and two null cell adenomas.
Relationship between marker expression and
recurrence
There was substantial variation in MIB-1 labelling among
the different tumours and also within the same tumour. In
the majority of cases (n = 22, 88%), the MIB-1-labelling
index was <3%; the proliferation index exceeded 3% in
only 12% of cases (n = 3), with one case in each of the
following groups: null cell adenoma, ACTH adenoma and
mixed GH/prolactin cell adenoma. Of note, cases with an
increased proliferation index were more likely to recur dur-
ing the follow-up period (p <0.0001, fig. 3). In the highly
proliferating tumours, 2 of 3 adenomas recurred within the
first year after the initial operation: the ACTH adenoma
and mixed GH/prolactin cell adenoma. After two surgeries
and postoperative radiotherapy, the latter example showed
a stationary residual lesion during follow-up. There was no
significant difference in outcome between patients who re-
ceived standard therapy or standard plus adjuvant therapy
(medical therapy or radiotherapy). Variation in SSTR ex-
pression was seen in the different pituitary adenoma sub-
Figure 5
Kaplan-Meier curve showing the different markers and recurrence-
free survival.
Eg5 = kinesin spindle protein; IL-8 = interleukin-8; SSTR =
somatostatin receptor; VEGFR-2 = vascular endothelial growth
factor receptor-2; vWF = von Willebrand-factor
types (fig. 4); however, as shown in fig. 5, SSTR expres-
sion (SSTR-1, p = 0.409; SSTR-2, p = 0.958; SSTR-3,
p = 0.852; SSTR-4, p = 0.246; SSTR-5, p = 0.912) and
expression of IL-8 (p = 0.741), vVW (p = 0.937) and
VEGFR-2 (p = 0.197) failed to correlate with recurrence.
Eg5 was not superior to MIB-1-labelling index with respect
to predicting recurrence-free survival (p = 0.733, fig. 4).
Hormone expression
Overall, 24% (n = 6) of all tumour cases recurred. Inter-
estingly, there was a tendency for recurrent tumours to ex-
press luteinising hormone (LH). A total of 67% of the re-
current tumours were immunoreactive for LH, with 50%
showing new positive LH expression or persistent LH ex-
pression in contrast to 2 LH-negative relapses. LH-negative
recurrent tumours were either pure ACTH- or GH-positive
adenomas.
Discussion
Recent advances in understanding the molecular
pathomechanisms of pituitary adenomas have proven use-
ful for developing novel therapeutic approaches. The major
signalling pathways affected by SSAs have been character-
ised providing additional potential targets for therapeutic
intervention in refractory cases. In fact, therapy with SSAs
is now considered the most important adjunct to surgery
and potential combination therapy with other medical ap-
proaches [42]. In the present study, we investigated the ex-
pression of SSTR, proliferation and angiogenesis markers
to ascertain their potential clinical and biological role in
different subtypes of pituitary adenoma. Not surprisingly,
pituitary adenomas generally showed proliferating indices
below 3%, with a higher labelling index considered a de-
fining feature of atypical adenomas [18]. Confirming pre-
vious studies, we found that the MIB-1 proliferation index
was related with recurrence (p <0.0001). Among the highly
proliferative tumours, recurrences were noted in 2 of 3 ad-
enomas within the first year after the initial surgery.
SSTR-expression appeared highly variable within and
among different tumour subtypes. Ramírez et al. [20] found
significant levels of SSTR-2 and SSTR-5 expression in
null cell adenomas. In our series, variable SSTR-expres-
sion was seen in the different PA subtypes (see fig. 5). Sim-
ilar results were observed by Plöckinger et al. in GH- and
GH/prolactin-secreting adenomas [7].
With the exception of the MIB-1 proliferation index (see
fig. 3), none of the markers analysed were predictive of re-
lapse. Interestingly, a tendency was seen for recurrent tu-
mours to express LH. A total of 67% of recurrent tumours
were immunoreactive for LH, with 50% showing new LH
positivity or persistent LH expression in contrast to 2 LH-
negative relapses. As a rule, these tumours present as mac-
roadenomas and incomplete tumour removal may explain
the relapses.
Eg5 is a microtubule-dependent motor protein (KSP) en-
coded by the KIF11 gene located at 10q24.1, with a
primary function in mitotic spindle formation. Liu et al.
[21] suggested a role for Eg5 in pancreatic tumourigenesis,
with adenosine triphosphatase- (ATPase-) dependent up-
regulation and enhanced cell proliferation seen in pancreat-
Original article Swiss Med Wkly. 2013;143:w13895
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ic cancer cell lines. In our study, we were unable to demon-
strate a relationship between Eg5 expression and recur-
rence (see fig. 4, p = 0.1145). More specifically, the 3 cases
with greater than 3% MIB-1 index (atypical adenomas)
showed no significant higher Eg5 expression compared
with typical adenomas.
Angiogenesis, an interactive process between tumour and
host cells, is required for tumour growth, progression and
metastasis [21, 25–27]. VEGF employs primarily
VEGFR-2, a receptor tyrosine kinase, to induce vascular
endothelial survival, proliferation and vessel permeability
[28, 29]. In 1999, Lloyd et al. reported lower VEGF im-
munostaining in normal pituitary glands compared with ad-
enomas, with even greater expression in pituitary carcino-
mas [30]. Subsequently, VEGFR-2 messenger ribonucleic
acid (mRNA) and protein over-expression was identified
in a series of adenomas, with highest expression in non-
functioning adenomas and GH-producing adenomas [31].
However, no difference was observed between VEGF ex-
pression and its receptors and tumour progression paramet-
ers, such as grade, proliferative index and vessel density
[22]. More recently, Western blot analysis of 56 pituit-
ary adenomas revealed that VEGF protein expression was
higher in prolactinomas compared with nonfunctioning,
GH- and ACTH-secreting adenomas [32]. Other studies
have observed absent or reduced immunostaining of vas-
cular VEGFR-2 in pituitary adenomas [33–36]. Neverthe-
less, McCabe et al. reported a strong over-expression of
VEGFR-2 mRNA (average 14-fold, maximum 233-fold)
in more than 100 human pituitary adenomas using quant-
itative polymerase chain reaction (PCR) [31]. In the same
study, enhanced VEGFR-2 protein expression was also
shown (by Western blotting) in several adenomas invest-
igated. Only oestrogen-induced prolactinomas in rats ex-
hibited over-expression of both VEGFR-2 and neuropilin-1
(NRP-1) [37, 38]. In our study, endothelial VEGFR-2 ex-
pression was expressed both in normal and pituitary ad-
enomas tissue. In contrast, Kuczynski et al. [39] found low
or undetectable VEGFR-2 in normal tissue and the pro-
portion of VEGFR2-positive vessels increased with tumour
grade. The survival rate of patients in one series correl-
ated with higher levels of IL-8 and VEGF [40]. We did not
observe any relationship between IL-8 and VEGFR-2 ex-
pression (see fig. 3), indicating the expression of these an-
giogenic factors is likely to be independent. The contra-
dictory findings regarding VEGFR-2 expression in human
pituitary adenomas need to be clarified in future studies.
Although we failed to observe a relationship between dif-
ferent SSTR subtypes, angiogenesis and proliferation
markers (except MIB-1 [Ki-67]) and disease progression,
there are several factors that may have interfered with the
interpretation of the data. As noted, the overall number of
tumours is rather low, and the tumour cohort consists of
different adenoma subtypes. These different pituitary ad-
enoma subtypes are likely to possess differences in biolo-
gical behaviour, which failed to emerge in the limited cases
available for study.
In conclusion, our study confirms previous observations
that the MIB-1 (Ki-67) labelling index represents a useful
prognostic marker, superior to Eg5, in patients with pituit-
ary adenomas. In addition, all adenomas analysed showed
expression of SSTR, Eg5, VEGFR-2, IL-8 and vWF, which
supports further investigation of these markers as targets
for non-invasive treatment. Although other small studies
have been published, additional large-scale studies need to
be performed to better understand the different roles of the
SSTR in pituitary adenomas and further investigate their
role as candidates for therapeutic targeting.
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Table 1: Patient characteristics.
Patient characteristics (n = 25)
Gender Histological adenoma subtypes
Males 16 ACTH cell adenomas 2 (8%)
Females 9 Prolactinomas 3 (12%)
Age (years) Mixed bicellular GH/prolactin cell adenomas 2 (8%)
Range 23–77 Gonadotroph adenomas 6 (24%)
Mean 55 Plurihormonal adenomas 7 (28%)
Males 62 Null cell adenomas 5 (20%)
Females 44 Clinical adenoma subtypes
Symptoms at presentation Functioning adenomas 8 (32%)
Headache 3 (12%) PRL-secreting adenomas 3 (12%)
Acromegaly 3 (12%) GH-secreting adenomas 2 (8%)
Visual disturbances 9 (36%) Gonadotropin secreting adenomas 3 (12%)
Amenorrhoea, galactorrhoea 1 (4%) Non-functioning adenomas 12 (48%)
Loss of libido 3 (12%) Silent adenomas 5 (20%)
Tiredness 2 (8%) Treatment
Dizziness 3 (12%) Surgery alone 18 (72%)
Gynecomastia 1 (4%) Surgery + postoperative medical therapy 4 (16%)
Size (cm) Preoperative medical therapy + surgery 1 (4%)
Range 0.5–7 Surgery + radiotherapy 2 (8%)
Mean 1.6
ACTH = adrenocorticotrophic hormone; GH = growth hormone; PRL = prolactin
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Figures (large format)
Figure 1
Immunohistochemical expression of the different markers‘ expression in a pituitary adenoma: (A) hematoxilin-eosin, (B) reticulin, (C) MIB-1
(Ki-67), (D) Eg5, (E) VEGFR-2, (F) vWF, (G) IL-8, (H) SSTR-1, (I) SSTR-2, (J) SSTR-3, (K) SSTR-4, (L) SSTR-5.
Eg5 = kinesin spindle protein; IL-8 = interleukin-8; SSTR = somatostatin receptor; VEGFR-2 = vascular endothelial growth factor receptor-2;
vWF = von Willebrand-factor
Figure 2
Kaplan-Meier curve showing age and recurrence free survival.
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Figure 3
Kaplan-Meier curve showing MIB-1 (Ki-67) proliferation index and time to recurrence: cases with higher MIB-1 proliferation index are more likely
to recur (p <0.0001).
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Figure 4
SSTR-, IL8-, Eg5-, VEGFR-2- and vWF-expression of the different pituitary adenoma subtypes. Note that the y-axes represent the mean
immunoreactivity score.
ACTH = adrenocorticotrophic hormone; Eg5 = kinesin spindle protein; GH = growth hormone; IL-8 = interleukin-8; Prl = prolactin; SSTR =
somatostatin receptor; VEGFR-2 = vascular endothelial growth facto receptorr-2; vWF = von Willebrand-factor
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Figure 5
Kaplan-Meier curve showing the different markers and recurrence-free survival.
Eg5 = kinesin spindle protein; IL-8 = interleukin-8; SSTR = somatostatin receptor; VEGFR-2 = vascular endothelial growth factor receptor-2;
vWF = von Willebrand-factor
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